Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108836
Filing Date
2025-08-14
Accepted
2025-08-14 16:03:05
Documents
70
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rntx-20250630.htm   iXBRL 10-Q 2157484
2 EX-3.5 rntx-ex3_5.htm EX-3.5 232464
3 EX-31.1 rntx-ex31_1.htm EX-31.1 17306
4 EX-31.2 rntx-ex31_2.htm EX-31.2 17542
5 EX-32.1 rntx-ex32_1.htm EX-32.1 8504
6 EX-32.2 rntx-ex32_2.htm EX-32.2 8495
  Complete submission text file 0000950170-25-108836.txt   9621183

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rntx-20250630.xsd EX-101.SCH 1391429
73 EXTRACTED XBRL INSTANCE DOCUMENT rntx-20250630_htm.xml XML 1532369
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38130 | Film No.: 251218573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)